Bayer has halted its late - stage human clinical trials of experimental uterine fibroids treatment vilaprisan . The company said it was a " precautionary measure " , taken after reviewing the results of long - term toxicology studies involving patients . Bayer said it expects peak annual sales of € 1bn ( $ 1.1 billion ) from vilaprisan .
Bayer has halted its late-stage human clinical trials of experimental uterine fibroids treatment vilaprisan. The company said it was a "precautionary measure", taken after receiving the results of long-term toxicology studies involving rodents. Bayer said it expected peak annual sales of €1bn ($1.1 billion) from vilaprisan.